Financial & Tax Architects LLC Has $8.13 Million Stock Holdings in AbbVie Inc. $ABBV

Financial & Tax Architects LLC decreased its stake in AbbVie Inc. (NYSE:ABBV) by 8.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 35,570 shares of the company’s stock after selling 3,372 shares during the quarter. AbbVie makes up about 1.8% of Financial & Tax Architects LLC’s holdings, making the stock its 14th biggest position. Financial & Tax Architects LLC’s holdings in AbbVie were worth $8,127,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of AbbVie by 0.3% during the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after acquiring an additional 448,554 shares in the last quarter. Legal & General Group Plc boosted its position in AbbVie by 4.3% during the third quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock valued at $2,779,426,000 after purchasing an additional 493,420 shares during the last quarter. Wellington Management Group LLP grew its stake in AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares in the last quarter. Amundi grew its stake in AbbVie by 15.6% in the third quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after purchasing an additional 1,414,621 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its position in AbbVie by 4.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company’s stock worth $2,241,363,000 after purchasing an additional 408,426 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

NYSE ABBV opened at $208.79 on Monday. The stock has a 50-day simple moving average of $221.58 and a 200 day simple moving average of $224.50. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The stock has a market capitalization of $369.17 billion, a PE ratio of 88.47, a P/E/G ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same period in the previous year, the business posted $2.16 EPS. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is presently 293.22%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Guggenheim reiterated a “buy” rating on shares of AbbVie in a report on Thursday, March 12th. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and raised their price objective for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Piper Sandler lifted their target price on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Berenberg Bank set a $275.00 target price on shares of AbbVie in a research report on Tuesday, January 20th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $253.15.

Insiders Place Their Bets

In other news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is owned by corporate insiders.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.